uro vaxom
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00521924)
Timeline
Indications
Mechanism of action
- Escherichia coliImmunity, active
Escherichia coli immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- om 89
- uro vaxom
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02591901 | Phase 2 | Jan 1, 2016 | Buckinghamshire Healthcare NHS Trust, Stoke Mandeville Hospital |
| NCT00521924 | Phase 3 | Jun 1, 2007 | AESCA Pharma GmbH, Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AESCA Pharma GmbH | For profit | 1 | 0 | 1 | 2007 |
| Buckinghamshire Healthcare NHS Trust | Government | 1 | 1 | 1 | 2016 |
| Merck | For profit | 1 | 1 | 1 | 2007 |
| Stoke Mandeville Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1